End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.57 CNY | +1.94% | +0.09% | -32.89% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With a 2024 P/E ratio at 26 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.89% | 222M | - | ||
-7.16% | 178B | C+ | ||
-1.23% | 107B | C | ||
-4.86% | 67.04B | A | ||
-4.29% | 47.24B | B- | ||
+10.32% | 44.62B | B- | ||
+8.14% | 42.5B | B+ | ||
+15.76% | 29.99B | B | ||
+15.53% | 25.22B | A- | ||
-5.88% | 24.14B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688026 Stock
- Ratings Guangzhou Jet Bio-Filtration Co., Ltd.